Biologics In Focus

Welcome to the December edition of Biologics in Focus, our monthly newsletter showcasing the latest highlights and innovations in the biologics industry.

In this edition, we explore how emerging biotechs can accelerate early-stage development through partnerships, highlight advancements in gene expression control with our enhanced GS® CHO Vector Technology, and provide expert insights on successful biologics tech transfers. This month, we also celebrate key milestones. These include the Synaffix-BigHat collaboration, the expansion of bioconjugation capabilities in Visp, and the successful completion of Lonza’s first GMP batch at our next-generation manufacturing facility in Portsmouth.

As we approach the new year, we extend our gratitude for your continued partnership and engagement with our content. Your support fosters meaningful collaboration, and we look forward to advancing our shared goals in the year ahead.

Join us in driving innovation and shaping the future of biologics in the coming year—one breakthrough at a time.

Insights and Analysis

How Emerging Biotechs Can Benefit by Partnering with a CDMO for Early Stage Development

The article explores how Contract Development and Manufacturing Organizations (CDMOs) can accelerate drug development for small biotech companies during the early stages. It highlights the importance of integrated services to minimize timelines, ensure flexibility, and streamline clinical and regulatory processes. Learn how our global expertise, technologies, and tailored solutions enable biotechs to advance therapies from feasibility studies to market readiness efficiently.

Enhanced GS® CHO Vector Technology for Improved Expression Control of Biotherapeutic Proteins

Watch this webinar to discover the advancements in gene expression systems for biotherapeutics. It highlights how our GS® CHO platform optimizes recombinant protein production by improving control over gene expression. This innovation enhances efficiency and productivity in developing high-quality therapeutic proteins, streamlining processes from discovery to manufacturing.

Considerations for the Successful Tech Transfer of a Biologics Upstream Process

The article on technology transfer considerations for biopharmaceuticals emphasizes the complexities of transferring biological drug processes across development stages. It covers key challenges, such as ensuring process consistency and addressing risks, while highlighting the importance of knowledge transfer and on-site visits. Dive into our holistic approach, which includes advanced expertise, cutting-edge technologies, and customized strategies to streamline and optimize technology transfers for both clinical and commercial scales.

Lonza in the Press

Q&A: Robust Supply Chains and Global Networks are Among Key Considerations When Choosing an mRNA CDMO

Choosing the right CDMO is crucial for successfully navigating the complexities of mRNA manufacturing. In a recent Q&A, our expert, Torsten Schmidt, highlights the importance of robust supply chains, cutting-edge technologies like LNP mixing devices, and regulatory expertise. Innovations in mRNA manufacturing and analytics are driving scalability, efficiency, and new therapeutic applications, underscoring the transformative potential of this modality.

Lonza Completes First GMP Batch at Next-Generation Mammalian Manufacturing Facility

Successfully completed the first GMP batch at its state-of-the-art mammalian manufacturing facility in Portsmouth, US. This next-generation facility leverages advanced bioprocessing technologies for scalable and efficient biologics production. The combination of automation, digitalization, and flexible design sets a new benchmark for manufacturing, enabling faster delivery of high-quality therapies worldwide.

Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing Suites

Lonza is expanding its bioconjugation capabilities in Visp, Switzerland, with two new manufacturing suites. This investment enhances its ability to produce complex biotherapeutics like antibody-drug conjugates (ADCs). The new suites will offer additional capacity and flexibility to meet growing global demand, reinforcing Lonza’s position as a leader in delivering innovative solutions for biopharma customers worldwide.

BigHat Licenses Synaffix’s Site-Specific ADC Technology Platform

BigHat Biosciences has partnered with Synaffix to license its antibody-drug conjugate (ADC) technology, including GlycoConnect™, HydraSpace™, and SYNtecan E linker-payload. This collaboration will integrate Synaffix’s platform into BigHat’s AI-driven protein engineering to accelerate ADC development.

Enhancing Drug Product Services to Support Growing Demand

Peter Droc, Head of Drug Product Services, discusses the company's new drug product services facility in Basel and key trends and challenges in biologics manufacturing. Lonza recently completed the expansion of its new drug product services facility in Basel Switzerland, adding a new facility for quality control and bioanalytics to support early and late-stage clinical and commercial drug product (DP) quality control (QC). The new facility allows DPS to double its capacity for the development and testing of parenteral dosage forms.

Key Upcoming Events

View more events.

Thank you for reading. Remember to subscribe so you never miss our monthly updates.

If you'd like to find out more about Lonza Biologics, you can visit our website or contact one of our team of experts.